Trevor A Crowell1, Kelly A Gebo1, Joel N Blankson1, P Todd Korthuis2, Baligh R Yehia3, Richard M Rutstein4, Richard D Moore1, Victoria Sharp5, Ank E Nijhawan6, W Christopher Mathews7, Lawrence H Hanau8, Roberto B Corales9, Robert Beil10, Charurut Somboonwit11, Howard Edelstein12, Sara L Allen13, Stephen A Berry1. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Public Health/Preventive Medicine, Oregon Health and Science University, Portland. 3. Department of Medicine, University of Pennsylvania Perelman School of Medicine. 4. Division of General Pediatrics, Children's Hospital of Philadelphia. 5. Center for Comprehensive Care, St Luke's Roosevelt Hospital Center. 6. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas. 7. Department of Medicine, University of California, San Diego. 8. Department of Medicine, Montefiore Medical Center. 9. Trillium Health, Rochester, New York. 10. Montefiore Medical Group, Bronx. 11. Tampa General Health Care, Florida. 12. Department of Internal Medicine, Alameda County Medical Center, Oakland, California. 13. Department of Medicine, Drexel University College of Medicine, Pennsylvania.
Abstract
BACKGROUND: Elite controllers spontaneously suppress human immunodeficiency virus (HIV) viremia but also demonstrate chronic inflammation that may increase risk of comorbid conditions. We compared hospitalization rates and causes among elite controllers to those of immunologically intact persons with medically controlled HIV. METHODS: For adults in care at 11 sites from 2005 to 2011, person-years with CD4 T-cell counts ≥350 cells/mm(2) were categorized as medical control, elite control, low viremia, or high viremia. All-cause and diagnostic category-specific hospitalization rates were compared between groups using negative binomial regression. RESULTS: We identified 149 elite controllers (0.4%) among 34 354 persons in care. Unadjusted hospitalization rates among the medical control, elite control, low-viremia, and high-viremia groups were 10.5, 23.3, 12.6, and 16.9 per 100 person-years, respectively. After adjustment for demographic and clinical factors, elite control was associated with higher rates of all-cause (adjusted incidence rate ratio, 1.77 [95% confidence interval, 1.21-2.60]), cardiovascular (3.19 [1.50-6.79]) and psychiatric (3.98 [1.54-10.28]) hospitalization than was medical control. Non-AIDS-defining infections were the most common reason for admission overall (24.1% of hospitalizations) but were rare among elite controllers (2.7%), in whom cardiovascular hospitalizations were most common (31.1%). CONCLUSIONS: Elite controllers are hospitalized more frequently than persons with medically controlled HIV and cardiovascular hospitalizations are an important contributor.
BACKGROUND: Elite controllers spontaneously suppress human immunodeficiency virus (HIV) viremia but also demonstrate chronic inflammation that may increase risk of comorbid conditions. We compared hospitalization rates and causes among elite controllers to those of immunologically intact persons with medically controlled HIV. METHODS: For adults in care at 11 sites from 2005 to 2011, person-years with CD4 T-cell counts ≥350 cells/mm(2) were categorized as medical control, elite control, low viremia, or high viremia. All-cause and diagnostic category-specific hospitalization rates were compared between groups using negative binomial regression. RESULTS: We identified 149 elite controllers (0.4%) among 34 354 persons in care. Unadjusted hospitalization rates among the medical control, elite control, low-viremia, and high-viremia groups were 10.5, 23.3, 12.6, and 16.9 per 100 person-years, respectively. After adjustment for demographic and clinical factors, elite control was associated with higher rates of all-cause (adjusted incidence rate ratio, 1.77 [95% confidence interval, 1.21-2.60]), cardiovascular (3.19 [1.50-6.79]) and psychiatric (3.98 [1.54-10.28]) hospitalization than was medical control. Non-AIDS-defining infections were the most common reason for admission overall (24.1% of hospitalizations) but were rare among elite controllers (2.7%), in whom cardiovascular hospitalizations were most common (31.1%). CONCLUSIONS: Elite controllers are hospitalized more frequently than persons with medically controlled HIV and cardiovascular hospitalizations are an important contributor.
Authors: Jack E Burkhalter; Carolyn M Springer; Rosy Chhabra; Jamie S Ostroff; Bruce D Rapkin Journal: Nicotine Tob Res Date: 2005-08 Impact factor: 4.244
Authors: Sophie Grabar; Hana Selinger-Leneman; Sophie Abgrall; Gilles Pialoux; Laurence Weiss; Dominique Costagliola Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Mohammad M Sajadi; Neil T Constantine; Dean L Mann; Manhattan Charurat; Elham Dadzan; Peter Kadlecik; Robert R Redfield Journal: J Acquir Immune Defic Syndr Date: 2009-04-01 Impact factor: 3.731
Authors: Priscilla Y Hsue; Peter W Hunt; Amanda Schnell; S Craig Kalapus; Rebecca Hoh; Peter Ganz; Jeffrey N Martin; Steven G Deeks Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks Journal: J Infect Dis Date: 2008-01-01 Impact factor: 5.226
Authors: Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks Journal: J Virol Date: 2008-10-22 Impact factor: 5.103
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Janet Karpinski; Ilona Hauber; Jan Chemnitz; Carola Schäfer; Maciej Paszkowski-Rogacz; Deboyoti Chakraborty; Niklas Beschorner; Helga Hofmann-Sieber; Ulrike C Lange; Adam Grundhoff; Karl Hackmann; Evelin Schrock; Josephine Abi-Ghanem; M Teresa Pisabarro; Vineeth Surendranath; Axel Schambach; Christoph Lindner; Jan van Lunzen; Joachim Hauber; Frank Buchholz Journal: Nat Biotechnol Date: 2016-02-22 Impact factor: 54.908
Authors: Elizabeth R Stevens; Kimberly A Nucifora; Qinlian Zhou; Ronald Scott Braithwaite; Charles M Cleland; Amanda S Ritchie; Alexandra H Kutnick; Marya V Gwadz Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal Journal: J Virol Date: 2018-02-12 Impact factor: 5.103
Authors: Jadrana T F Toich; Paul A Taylor; Martha J Holmes; Suril Gohel; Mark F Cotton; Els Dobbels; Barbara Laughton; Francesca Little; Andre J W van der Kouwe; Bharat Biswal; Ernesta M Meintjes Journal: Front Hum Neurosci Date: 2018-01-11 Impact factor: 3.169